Article

Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients

Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY.
The Journal of Clinical Psychiatry (Impact Factor: 5.5). 03/1994; 55(2):66-9.
Source: PubMed

ABSTRACT

Although panic disorder is generally responsive to single antidepressant pharmacotherapy, a substantial percentage of patients fail either to respond adequately or to maintain a therapeutic response.
The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine. Those patients taking a TCA had fluoxetine added and those patients taking fluoxetine had a TCA added.
All seven patients showed an improvement in antipanic response to the combination treatment.
The current case series is the first, to our knowledge, to suggest that the combination of a TCA and fluoxetine may provide a viable pharmacotherapeutic option for panic disorder patients who have failed to respond to an adequate trial of either a TCA or fluoxetine. Appropriate controlled studies are recommended.

0 Followers
 · 
7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Available evidence suggests that panic disorder causes severe degradation in quality of life and work productivity (WP). There is growing interest in evaluating pharmacotherapy in panic disorder, but its effects on quality of life or WP have not been assessed, perhaps because appropriate scales have not been validated specifically in panic disorder. This study examines the internal consistency, test/retest reliability, construct validity and responsiveness of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and the Work Productivity and Activity Impairment (WPAI) questionnaire when used in panic disorder. Clinical evaluations were performed at baseline and at weeks 4 and 8. Patients self-administered the SF-36 and WPAI at weeks 4 and 8. The SF-36 performed well in terms of internal consistency and test/retest reliability, with the exception of the ‘role limits due to emotional health’ scale. For the other scales, Cronbach’s α ≥ 0.83 and correlations between week 4 and 8 scores were significant (p < 0.01) for patients with a stable clinical condition. There were no significant differences in mean SF-36 scores obtained at weeks 4 and 8 for stable patients. Construct validity was also supported. As hypothesised, we detected significant correlations between the SF-36 Mental Health Component Summary (MCS) and clinical measures of disease severity. Evidence of responsiveness was also obtained: patients with fewer panic attacks during the second month of follow-up improved on the MCS, while those with a stable or increased frequency of panic attacks did not (8 point versus 1 point improvement, p < 0.01). The WPAI did not perform as well, perhaps due to a combination of limited sample size and high variability in WPAI scores. Only 44 of 77 individuals were employed at baseline and completed WPAI items. The standard deviation for the measure ‘overall work productivity’ was more than half the mean score. Neither test/retest reliability nor construct validity were demonstrated. Although WPAI scores improved for patients showing clinical improvement, this result is incongruous with the lack of evidence supporting its validity. The SF-36 is a valid, reliable and responsive measure of QOL in panic disorder. It is unclear whether the WPAI possesses these properties when used in panic disorder.
    No preview · Article · Mar 1997 · Disease Management and Health Outcomes
  • [Show abstract] [Hide abstract]
    ABSTRACT: This tenth anniversary review/update of fluoxetine concentrates on the past 5 years of its clinical application. The mechanism of action of fluoxetine; its metabolism; its efficacy in patients with various diagnostic subgroups of depression, patients with coincident medical disease, children and adolescents with depression, patients with eating disorders, and patients with obsessive-compulsive disorder (OCD); its long-term (maintenance) efficacy; its side effects and toxicity; and pharmacoeconomic considerations are reviewed. Pharmacotherapy is currently the only proven method for treating major depressive disorder that is applicable to all levels of severity of major depressive illness. Since its introduction 10 years ago, fluoxetine has been available to psychiatrists, primary care physicians, and other nonpsychiatric physicians as full-dose effective pharmacotherapy for patients with depression. Fluoxetine has been widely prescribed by physicians knowledgeable in pharmacology and in the treatment of depression because of its proven efficacy (ie, equal to that of tricyclic antidepressants [TCAs]), its ease of administration (with full therapeutic dosing usually starting from day 1), its generally benign side-effect profile, its remarkable safety in over-dose, and its proven effectiveness in the most common depressed patient population--anxious, agitated, depressed patients--as well as in patients with various subtypes and severities of depression. In more recent years it has also proved effective in the treatment of bulimia, an entity for which only limited or inadequate treatment options had been previously available. In OCD, fluoxetine, with its more acceptable side-effect profile and greater ease of dosing, presents a favorable alternative to previous drug therapy and is useful in treating both obsessions and compulsions. Fluoxetine is currently recognized among clinicians as efficacious in treating anxiety disorders and is being used successfully in special depressed populations such as patients with medical comorbidity, elderly patients, adolescents, and children. Rapid discontinuation or missed doses of short-half-life selective serotonin reuptake inhibitors, TCAs, and heterocyclic antidepressants are associated with withdrawal symptoms of a somatic and psychological nature, which cannot only be disruptive, but can also be suggestive of relapse or recurrence of depression. In striking contrast to these short-half-life antidepressants, fluoxetine is rarely associated with such sequelae on sudden discontinuation or missed doses. This preventive effect against withdrawal symptoms on discontinuation of fluoxetine is attributed to the unique extended half-life of this antidepressant. Current studies show that the overall increased effectiveness of fluoxetine in treating depression compensates for its higher cost, compared with older drugs, by reducing the need for physician contact because of increased compliance and less need of titration, and by reducing premature patient discontinuation, thereby yielding fewer relapses, less recurrence, and less reutilization of mental health services.
    No preview · Article · Sep 1997 · Clinical Therapeutics
  • [Show abstract] [Hide abstract]
    ABSTRACT: A decade of remarkable research in neuroscience has given us a much more complete picture of how the central nervous system works and, in some instances, how the brain does not work when patients develop depression. Preclinical and clinical studies have shown that stimulation of the serotonergic system leads to noradrenergic effects and vice versa, confirming that the serotonin and norepinephrine systems are intimately connected in the central nervous system. Although medications that target the serotonergic neurotransmitter system have recently dominated antidepressant therapy, atypical antidepressants--with either mixed serotonergic and noradrenergic effects or exclusively noradrenergic effects--have been shown to be clinically efficacious medications. This increased understanding of the interrelationship between neurotransmitter systems has renewed interest in the role of neurotransmitters other than serotonin in the treatment of depression. With the introduction of reboxetine, a very selective norepinephrine reuptake inhibitor, researchers have had an opportunity to study the unique effects of norepinephrine in the etiology and treatment of depression. Ultimately, differences in neurotransmitter profiles may influence therapeutic potentials of antidepressants. For example, influencing norepinephrine may affect the expression of energy and interest, while influencing serotonin may affect impulse control and influencing dopamine may affect drive. Clinicians now have a range of antidepressants with variable neurotransmitter effects, different side effect profiles, and some interesting differences in functional utility in their armamentarium for treating depression.
    No preview · Article · Feb 2000 · The Journal of Clinical Psychiatry
Show more